JP2009538134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538134A5 JP2009538134A5 JP2009512107A JP2009512107A JP2009538134A5 JP 2009538134 A5 JP2009538134 A5 JP 2009538134A5 JP 2009512107 A JP2009512107 A JP 2009512107A JP 2009512107 A JP2009512107 A JP 2009512107A JP 2009538134 A5 JP2009538134 A5 JP 2009538134A5
- Authority
- JP
- Japan
- Prior art keywords
- nox protein
- protein
- item
- nox
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 708
- 108090000623 proteins and genes Proteins 0.000 claims description 708
- 230000035772 mutation Effects 0.000 claims description 129
- 238000000034 method Methods 0.000 claims description 121
- 230000009257 reactivity Effects 0.000 claims description 114
- 238000010494 dissociation reaction Methods 0.000 claims description 108
- 230000005593 dissociations Effects 0.000 claims description 108
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 105
- 239000001301 oxygen Substances 0.000 claims description 105
- 229910052760 oxygen Inorganic materials 0.000 claims description 105
- 102000001554 Hemoglobins Human genes 0.000 claims description 55
- 108010054147 Hemoglobins Proteins 0.000 claims description 55
- 150000003278 haem Chemical class 0.000 claims description 51
- 238000006701 autoxidation reaction Methods 0.000 claims description 45
- 239000008280 blood Substances 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 22
- 102000008300 Mutant Proteins Human genes 0.000 claims description 13
- 108010021466 Mutant Proteins Proteins 0.000 claims description 13
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 230000001146 hypoxic effect Effects 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010059484 Haemodilution Diseases 0.000 claims description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 241000253373 Caldanaerobacter subterraneus subsp. tengcongensis Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 31
- 239000007789 gas Substances 0.000 claims 14
- 239000002609 medium Substances 0.000 claims 6
- 238000007254 oxidation reaction Methods 0.000 claims 5
- 239000006143 cell culture medium Substances 0.000 claims 4
- 230000010261 cell growth Effects 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 102000004722 NADPH Oxidases Human genes 0.000 claims 2
- 108010002998 NADPH Oxidases Proteins 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 102100033130 T-box transcription factor T Human genes 0.000 claims 1
- 101710086566 T-box transcription factor T Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 90
- 108090000144 Human Proteins Proteins 0.000 description 31
- 102000003839 Human Proteins Human genes 0.000 description 31
- 108010077805 Bacterial Proteins Proteins 0.000 description 22
- 241000223997 Toxoplasma gondii Species 0.000 description 9
- 241000239246 Nephrops norvegicus Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 241001235572 Balantioides coli Species 0.000 description 4
- 241000018427 Iphisa elegans Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102220469353 Putative uncharacterized protein URB1-AS1_N74A_mutation Human genes 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102220040905 rs150548839 Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 102220467093 Apoptosis regulator BAX_M74E_mutation Human genes 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92150506P | 2006-05-22 | 2006-05-22 | |
| US60/921,505 | 2006-05-22 | ||
| PCT/US2007/012184 WO2007139791A2 (en) | 2006-05-22 | 2007-05-21 | Compositions and methods for the delivery of oxygen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014180140A Division JP6118772B2 (ja) | 2006-05-22 | 2014-09-04 | 一酸化窒素の送達のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538134A JP2009538134A (ja) | 2009-11-05 |
| JP2009538134A5 true JP2009538134A5 (enExample) | 2010-07-22 |
| JP5698906B2 JP5698906B2 (ja) | 2015-04-08 |
Family
ID=38779160
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512107A Active JP5698906B2 (ja) | 2006-05-22 | 2007-05-21 | 一酸化窒素の送達のための組成物および方法 |
| JP2009512098A Active JP5698905B2 (ja) | 2006-05-22 | 2007-05-21 | 一酸化窒素の送達のための方法 |
| JP2014180132A Active JP6118296B2 (ja) | 2006-05-22 | 2014-09-04 | 一酸化窒素の送達のための方法 |
| JP2014180140A Active JP6118772B2 (ja) | 2006-05-22 | 2014-09-04 | 一酸化窒素の送達のための組成物および方法 |
| JP2017061455A Active JP6458070B2 (ja) | 2006-05-22 | 2017-03-27 | 一酸化窒素の送達のための組成物および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512098A Active JP5698905B2 (ja) | 2006-05-22 | 2007-05-21 | 一酸化窒素の送達のための方法 |
| JP2014180132A Active JP6118296B2 (ja) | 2006-05-22 | 2014-09-04 | 一酸化窒素の送達のための方法 |
| JP2014180140A Active JP6118772B2 (ja) | 2006-05-22 | 2014-09-04 | 一酸化窒素の送達のための組成物および方法 |
| JP2017061455A Active JP6458070B2 (ja) | 2006-05-22 | 2017-03-27 | 一酸化窒素の送達のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US8404632B2 (enExample) |
| EP (7) | EP2463294B1 (enExample) |
| JP (5) | JP5698906B2 (enExample) |
| CN (5) | CN104689300B (enExample) |
| AU (2) | AU2007268052B2 (enExample) |
| BR (2) | BRPI0711901A2 (enExample) |
| CA (2) | CA2653080C (enExample) |
| DK (4) | DK2032156T3 (enExample) |
| ES (4) | ES2399662T3 (enExample) |
| IN (2) | IN2013MN00601A (enExample) |
| NZ (4) | NZ594457A (enExample) |
| WO (2) | WO2007139791A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2463294B1 (en) | 2006-05-22 | 2016-10-19 | The Regents of The University of California | Compositions and methods for the delivery of nitric oxide |
| US20110243849A1 (en) * | 2010-04-02 | 2011-10-06 | Marletta Michael A | Heme-binding photoactive polypeptides and methods of use thereof |
| EP3922643A1 (en) | 2013-01-07 | 2021-12-15 | Omniox, Inc. | Polymeric forms of h-nox proteins |
| SG10201908269SA (en) * | 2015-03-17 | 2019-10-30 | Omniox Inc | Modulation of tumor immunity by protein-mediated o2 delivery |
| BR112018016829A2 (pt) * | 2016-02-16 | 2018-12-26 | Omniox Inc | método para tratar acidente vascular cerebral em um indivíduo, método para administrar oxigênio a um indivíduo, método para tratar um ataque isquêmico transitório em um indivíduo, método para tratar uma lesão cerebral hipóxica em um indivíduo, composição, composição farmacêutica, uso de uma composição, kit e método para preparar uma composição |
| JP6467073B2 (ja) * | 2018-01-04 | 2019-02-06 | オムニオクス， インコーポレイテッド | Ｈ−ｎｏｘタンパク質の重合体形態 |
| WO2020037052A1 (en) | 2018-08-15 | 2020-02-20 | Omniox, Inc. | H-nox proteins for treating cardiovascular and pulmonary conditions |
| JP2021535739A (ja) | 2018-08-27 | 2021-12-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 下流精製でのラマン分光法の使用 |
| KR102776925B1 (ko) | 2019-06-25 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| PH12022551441A1 (en) | 2019-12-24 | 2023-11-20 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| US20240043427A1 (en) | 2020-05-01 | 2024-02-08 | Gilead Sciences, Inc. | Cd73 compounds |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| TW202519517A (zh) | 2023-07-26 | 2025-05-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6022849A (en) * | 1987-05-16 | 2000-02-08 | Baxter Biotech Technology Saarl | Mutant recombinant hemoglobins containing heme pocket mutations |
| US5731454A (en) * | 1990-02-12 | 1998-03-24 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
| AU6766994A (en) | 1994-04-01 | 1995-10-23 | Unisyn Technologies, Inc. | Culture media additives for hollow fiber bioreactors |
| JP4583510B2 (ja) * | 1997-02-28 | 2010-11-17 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 無細胞系による酸素輸送の最適化のための方法と組成物 |
| WO1998050430A2 (en) | 1997-05-02 | 1998-11-12 | Somatogen, Inc. | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
| DE19837015C2 (de) * | 1998-08-14 | 2003-03-20 | Vasopharm Biotech Gmbh | Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1) |
| US6773613B1 (en) * | 1998-10-15 | 2004-08-10 | Sangart, Inc. | Method for production of stroma-free hemoglobin |
| ATE553782T1 (de) * | 1999-12-22 | 2012-05-15 | Scripps Research Inst | Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung |
| CA2410953A1 (en) * | 2000-06-29 | 2002-01-10 | Incyte Genomics, Inc. | Adenylyl and guanylyl cyclases |
| US20030096240A1 (en) * | 2000-09-19 | 2003-05-22 | Ferid Murad | Genomic organization of mouse and human sGC |
| US6780849B2 (en) * | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
| US20030153491A1 (en) * | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| JP4873860B2 (ja) * | 2002-08-30 | 2012-02-08 | バイオレクシス ファーマシューティカル コーポレーション | 改変トランスフェリン融合タンパク質 |
| CN1660100A (zh) * | 2002-12-09 | 2005-08-31 | 上海倍艺医药科技有限公司 | 一种治疗糖尿病及其并发症的药物 |
| EP2463294B1 (en) | 2006-05-22 | 2016-10-19 | The Regents of The University of California | Compositions and methods for the delivery of nitric oxide |
-
2007
- 2007-05-21 EP EP11189807.8A patent/EP2463294B1/en active Active
- 2007-05-21 DK DK07795174.7T patent/DK2032156T3/da active
- 2007-05-21 ES ES07795174T patent/ES2399662T3/es active Active
- 2007-05-21 EP EP07795153.1A patent/EP2040740B1/en active Active
- 2007-05-21 CA CA2653080A patent/CA2653080C/en active Active
- 2007-05-21 AU AU2007268052A patent/AU2007268052B2/en active Active
- 2007-05-21 CN CN201410766335.4A patent/CN104689300B/zh active Active
- 2007-05-21 CN CN201810357346.5A patent/CN108273040A/zh active Pending
- 2007-05-21 ES ES07795153.1T patent/ES2525226T3/es active Active
- 2007-05-21 DK DK11189807.8T patent/DK2463294T3/en active
- 2007-05-21 JP JP2009512107A patent/JP5698906B2/ja active Active
- 2007-05-21 CA CA2653101A patent/CA2653101C/en active Active
- 2007-05-21 DK DK07795153.1T patent/DK2040740T3/en active
- 2007-05-21 EP EP07795174A patent/EP2032156B1/en active Active
- 2007-05-21 EP EP11189812A patent/EP2463296A1/en not_active Withdrawn
- 2007-05-21 EP EP11189814.4A patent/EP2463297B1/en active Active
- 2007-05-21 US US12/302,004 patent/US8404632B2/en active Active
- 2007-05-21 AU AU2007268028A patent/AU2007268028B2/en active Active
- 2007-05-21 NZ NZ594457A patent/NZ594457A/xx unknown
- 2007-05-21 IN IN601MUN2013 patent/IN2013MN00601A/en unknown
- 2007-05-21 CN CN201610487363.1A patent/CN106075388B/zh active Active
- 2007-05-21 NZ NZ573004A patent/NZ573004A/en unknown
- 2007-05-21 ES ES11189814.4T patent/ES2611157T3/es active Active
- 2007-05-21 JP JP2009512098A patent/JP5698905B2/ja active Active
- 2007-05-21 ES ES11189807.8T patent/ES2610653T3/es active Active
- 2007-05-21 NZ NZ594456A patent/NZ594456A/xx unknown
- 2007-05-21 IN IN600MUN2013 patent/IN2013MN00600A/en unknown
- 2007-05-21 BR BRPI0711901-1A patent/BRPI0711901A2/pt not_active Application Discontinuation
- 2007-05-21 DK DK11189814.4T patent/DK2463297T3/en active
- 2007-05-21 NZ NZ573003A patent/NZ573003A/en unknown
- 2007-05-21 CN CN200780027797.2A patent/CN101495134B/zh active Active
- 2007-05-21 CN CN200780027798.7A patent/CN101495506B/zh active Active
- 2007-05-21 WO PCT/US2007/012184 patent/WO2007139791A2/en not_active Ceased
- 2007-05-21 WO PCT/US2007/012133 patent/WO2007139767A2/en not_active Ceased
- 2007-05-21 EP EP11189818A patent/EP2474554A3/en not_active Withdrawn
- 2007-05-21 US US12/302,002 patent/US8404631B2/en active Active
- 2007-05-21 EP EP11189808A patent/EP2463295A1/en not_active Withdrawn
- 2007-05-21 BR BRPI0711767A patent/BRPI0711767B8/pt active IP Right Grant
-
2013
- 2013-02-20 US US13/772,283 patent/US20130289252A1/en not_active Abandoned
- 2013-02-20 US US13/772,281 patent/US20130288970A1/en not_active Abandoned
-
2014
- 2014-09-04 JP JP2014180132A patent/JP6118296B2/ja active Active
- 2014-09-04 JP JP2014180140A patent/JP6118772B2/ja active Active
- 2014-09-17 US US14/489,395 patent/US9493526B2/en active Active
- 2014-09-18 US US14/490,597 patent/US9493527B2/en active Active
-
2016
- 2016-10-12 US US15/292,012 patent/US10202428B2/en active Active
-
2017
- 2017-03-27 JP JP2017061455A patent/JP6458070B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538134A5 (enExample) | ||
| JP6458070B2 (ja) | 一酸化窒素の送達のための組成物および方法 | |
| JP2009538133A5 (enExample) | ||
| WO2004106373A1 (en) | Erythropoietin conjugate compounds with extended half-lives | |
| TWI400081B (zh) | 肽類及與受體結合之化合物 | |
| US20120059153A1 (en) | Methods for preparing stable deoxygenated peg-hemoglobin conjugate solutions comprising an antioxidant | |
| AU2013201114A1 (en) | Compositions and Methods for the Delivery of Nitric Oxide | |
| AU2013201117A1 (en) | Compositions and Methods for the Delivery of Oxygen | |
| Wiercioch et al. | Uptake of radiolabelled endomorphins by experimental mammary adenocarcinoma | |
| HK1137181A (en) | Compositions and methods for the delivery of oxygen | |
| HK1172913A (en) | Compositions and methods for the delivery of oxygen | |
| HK1172037A (en) | Compositions and methods for the delivery of oxygen | |
| HK1129688B (en) | Compositions and methods for the delivery of oxygen | |
| HK1123811B (en) | Use of peptides that bind to tpo receptor |